NICE draft guidance recommends two, rejects three ovarian cancer drugs
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has recommended two ovarian cancer drugs, Janssen's Caelyx (pegylated liposomal doxorubicin hydrochloride) and paclitaxel, for use on the National Health Service in draft guidance issued 27 September. However, the institute has rejected three others, including PharmaMar's anticancer Yondelis (trabectedin).